Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Quality of Life of Latino and Non-Latino Youth With Sickle Cell Disease as Reported by Parents and Youth.

Osborne JC, Green NS, Smaldone AM.

Hisp Health Care Int. 2020 Mar 3:1540415320908525. doi: 10.1177/1540415320908525. [Epub ahead of print]

PMID:
32124643
2.

End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Farrell AT, Panepinto J, Desai AA, Kassim AA, Lebensburger J, Walters MC, Bauer DE, Blaylark RM, DiMichele DM, Gladwin MT, Green NS, Hassell K, Kato GJ, Klings ES, Kohn DB, Krishnamurti L, Little J, Makani J, Malik P, McGann PT, Minniti C, Morris CR, Odame I, Oneal PA, Setse R, Sharma P, Shenoy S.

Blood Adv. 2019 Dec 10;3(23):4002-4020. doi: 10.1182/bloodadvances.2019000883.

3.

Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study.

Green NS, Munube D, Bangirana P, Buluma LR, Kebirungi B, Opoka R, Mupere E, Kasirye P, Kiguli S, Birabwa A, Kawooya MS, Lubowa SK, Sekibira R, Kayongo E, Hume H, Elkind M, Peng W, Li G, Rosano C, LaRussa P, Minja FJ, Boehme A, Idro R.

BMC Pediatr. 2019 Oct 25;19(1):381. doi: 10.1186/s12887-019-1758-2.

4.

HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.

Smaldone A, Manwani D, Aygun B, Smith-Whitley K, Jia H, Bruzzese JM, Findley S, Massei J, Green NS.

BMC Pediatr. 2019 Oct 15;19(1):354. doi: 10.1186/s12887-019-1746-6.

5.

Amphibian Monitoring in Hardwood Forests: Optimizing Methods for Contaminant-Based Compensatory Restorations.

Kunz BK, Waddle JH, Green NS.

Integr Environ Assess Manag. 2019 Aug 5. doi: 10.1002/ieam.4202. [Epub ahead of print]

PMID:
31379053
6.

Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Smaldone A, Manwani D, Green NS.

Pediatr Blood Cancer. 2019 Jul;66(7):e27740. doi: 10.1002/pbc.27740. Epub 2019 Apr 2.

7.

Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic.

Chen CJ, Bakeera-Kitaka S, Mupere E, Kasirye P, Munube D, Idro R, Hume H, Pfeffer B, LaRussa P, Green NS.

J Paediatr Child Health. 2019 Jul;55(7):795-801. doi: 10.1111/jpc.14291. Epub 2018 Nov 9.

PMID:
30411430
8.

Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.

Marks LJ, Munube D, Kasirye P, Mupere E, Jin Z, LaRussa P, Idro R, Green NS.

Glob Pediatr Health. 2018 May 14;5:2333794X18774970. doi: 10.1177/2333794X18774970. eCollection 2018.

9.

HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.

Smaldone A, Findley S, Manwani D, Jia H, Green NS.

J Pediatr. 2018 Jun;197:177-185.e2. doi: 10.1016/j.jpeds.2018.01.054. Epub 2018 Mar 20.

10.

An Online Calculator to Estimate the Impact of Changes in Breastfeeding Rates on Population Health and Costs.

Stuebe AM, Jegier BJ, Schwarz EB, Green BD, Reinhold AG, Colaizy TT, Bogen DL, Schaefer AJ, Jegier JT, Green NS, Bartick MC.

Breastfeed Med. 2017 Dec;12(10):645-658. doi: 10.1089/bfm.2017.0083. Epub 2017 Sep 14.

PMID:
28906133
11.

Optical Coherence Tomography Angiography and Ultra-widefield Fluorescein Angiography for Early Detection of Adolescent Sickle Retinopathy.

Pahl DA, Green NS, Bhatia M, Lee MT, Chang JS, Licursi M, Briamonte C, Smilow E, Chen RWS.

Am J Ophthalmol. 2017 Nov;183:91-98. doi: 10.1016/j.ajo.2017.08.010. Epub 2017 Aug 30.

12.

New Ways to Detect Pediatric Sickle Cell Retinopathy: A Comprehensive Review.

Pahl DA, Green NS, Bhatia M, Chen RWS.

J Pediatr Hematol Oncol. 2017 Nov;39(8):618-625. doi: 10.1097/MPH.0000000000000919. Review.

13.

Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.

Green NS, Manwani D, Matos S, Hicks A, Soto L, Castillo Y, Ireland K, Stennett Y, Findley S, Jia H, Smaldone A.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26689. Epub 2017 Jun 23.

14.

Enhanced Long-Term Brain Magnetic Resonance Imaging Evaluation of Children with Sickle Cell Disease after Hematopoietic Cell Transplantation.

Green NS, Bhatia M, Griffith EY, Qureshi M, Briamonte C, Savone M, Sands S, Lee MT, Lignelli A, Brickman AM.

Biol Blood Marrow Transplant. 2017 Apr;23(4):670-676. doi: 10.1016/j.bbmt.2017.01.007. Epub 2017 Jan 9.

15.

Assessment of Transition Readiness in Adolescents with Sickle Cell Disease and their Caretakers, A single institution experience.

Kwarteng-Siaw M, Paintsil V, Toboh CK, Owusu-Ansah A, Green NS.

Int J Hematol Res. 2017;3(1):171-179. doi: 10.17554/j.issn.2409-3548.2017.03.47. Epub 2017 Dec 12.

16.

Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.

Green NS, Manwani D, Qureshi M, Ireland K, Sinha A, Smaldone AM.

Pediatr Blood Cancer. 2016 Dec;63(12):2146-2153. doi: 10.1002/pbc.26161. Epub 2016 Aug 30.

17.

Phenotypic Heterogeneity of Neutropenia and Gastrointestinal Illness Associated with G6PC3 Founder Mutation.

Glasser CL, Picoraro JA, Jain P, Kinberg S, Rustia E, Gross Margolis K, Anyane-Yeboa K, Iglesias AD, Green NS.

J Pediatr Hematol Oncol. 2016 Oct;38(7):e243-7. doi: 10.1097/MPH.0000000000000660.

PMID:
27571123
18.

Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation.

Kemper AR, Brosco J, Comeau AM, Green NS, Grosse SD, Jones E, Kwon JM, Lam WK, Ojodu J, Prosser LA, Tanksley S.

Genet Med. 2017 Jan;19(1):121-126. doi: 10.1038/gim.2016.68. Epub 2016 Jun 23.

19.

Family, Community, and Health System Considerations for Reducing the Burden of Pediatric Sickle Cell Disease in Uganda Through Newborn Screening.

Green NS, Mathur S, Kiguli S, Makani J, Fashakin V, LaRussa P, Lyimo M, Abrams EJ, Mulumba L, Mupere E.

Glob Pediatr Health. 2016 Apr 7;3:2333794X16637767. doi: 10.1177/2333794X16637767. eCollection 2016.

20.

Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Smaldone A, Findley S, Bakken S, Matiz LA, Rosenthal SL, Jia H, Matos S, Manwani D, Green NS.

Contemp Clin Trials. 2016 Jul;49:134-42. doi: 10.1016/j.cct.2016.06.004. Epub 2016 Jun 17.

21.

Community Health Workers as Support for Sickle Cell Care.

Hsu LL, Green NS, Donnell Ivy E, Neunert CE, Smaldone A, Johnson S, Castillo S, Castillo A, Thompson T, Hampton K, Strouse JJ, Stewart R, Hughes T, Banks S, Smith-Whitley K, King A, Brown M, Ohene-Frempong K, Smith WR, Martin M.

Am J Prev Med. 2016 Jul;51(1 Suppl 1):S87-98. doi: 10.1016/j.amepre.2016.01.016.

22.

Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State.

Anders DG, Tang F, Ledneva T, Caggana M, Green NS, Wang Y, Sturman LS.

Am J Prev Med. 2016 Jul;51(1 Suppl 1):S31-8. doi: 10.1016/j.amepre.2016.01.001.

23.

A framework for assessing outcomes from newborn screening: on the road to measuring its promise.

Hinton CF, Homer CJ, Thompson AA, Williams A, Hassell KL, Feuchtbaum L, Berry SA, Comeau AM, Therrell BL, Brower A, Harris KB, Brown C, Monaco J, Ostrander RJ, Zuckerman AE, Kaye C, Dougherty D, Greene C, Green NS; Follow-up and Treatment Sub-committee of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC).

Mol Genet Metab. 2016 Aug;118(4):221-9. doi: 10.1016/j.ymgme.2016.05.017. Epub 2016 May 31.

24.

Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review.

Goldenberg AJ, Comeau AM, Grosse SD, Tanksley S, Prosser LA, Ojodu J, Botkin JR, Kemper AR, Green NS.

Matern Child Health J. 2016 Mar;20(3):693-700. doi: 10.1007/s10995-015-1869-9.

25.

Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.

Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee.

J Clin Pharmacol. 2016 Mar;56(3):298-306. doi: 10.1002/jcph.598. Epub 2015 Oct 15.

26.

Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1.

Grieco AJ, Billett HH, Green NS, Driscoll MC, Bouhassira EE.

PLoS One. 2015 Jun 8;10(6):e0129431. doi: 10.1371/journal.pone.0129431. eCollection 2015.

27.

Cell free DNA testing-interpretation of results using an online calculator.

Grace MR, Hardisty E, Green NS, Davidson E, Stuebe AM, Vora NL.

Am J Obstet Gynecol. 2015 Jul;213(1):30.e1-30.e4. doi: 10.1016/j.ajog.2015.05.004. Epub 2015 May 5.

PMID:
25957020
28.

Adolescent and parent use of new technologies for health communication: a study in an urban latino community.

Smaldone A, Stockwell MS, Osborne JC, Cortes Y, Bekele E, Green NS.

J Public Health Res. 2015 Feb 19;4(1):376. doi: 10.4081/jphr.2015.376. eCollection 2015 Feb 20.

29.

Sickle cell in Latin America and the United States [corrected].

Huttle A, Maestre GE, Lantigua R, Green NS.

Pediatr Blood Cancer. 2015 Jul;62(7):1131-6. doi: 10.1002/pbc.25450. Epub 2015 Mar 2. Review. Erratum in: Pediatr Blood Cancer. 2015 Aug;62(8):1493.

PMID:
25732067
30.

Metal-enhanced fluorescence of dye-doped silica nano particles.

Gunawardana KB, Green NS, Bumm LA, Halterman RL.

J Fluoresc. 2015 Mar;25(2):311-7. doi: 10.1007/s10895-015-1510-8. Epub 2015 Jan 28.

PMID:
25627927
31.

Interactions of DNA with graphene and sensing applications of graphene field-effect transistor devices: a review.

Green NS, Norton ML.

Anal Chim Acta. 2015 Jan 1;853:127-142. doi: 10.1016/j.aca.2014.10.023. Epub 2014 Oct 18. Review.

PMID:
25467454
32.

Mortality of New York children with sickle cell disease identified through newborn screening.

Wang Y, Liu G, Caggana M, Kennedy J, Zimmerman R, Oyeku SO, Werner EM, Grant AM, Green NS, Grosse SD.

Genet Med. 2015 Jun;17(6):452-9. doi: 10.1038/gim.2014.123. Epub 2014 Sep 25.

33.

Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease.

Pashankar FD, Manwani D, Lee MT, Green NS.

J Pediatr Hematol Oncol. 2015 Apr;37(3):242-3. doi: 10.1097/MPH.0000000000000251. No abstract available.

34.

A step forward back to (induced) fetal.

Green NS.

Blood. 2014 Aug 14;124(7):993-5. doi: 10.1182/blood-2014-06-582445. No abstract available.

35.

Do difficulties in swallowing medication impede the use of hydroxyurea in children?

Bekele E, Thornburg CD, Brandow AM, Sharma M, Smaldone AM, Jin Z, Green NS.

Pediatr Blood Cancer. 2014 Sep;61(9):1536-9. doi: 10.1002/pbc.25073. Epub 2014 Apr 17.

36.

Pediatric hematology providers on referral for transplant evaluation for sickle cell disease: a regional perspective.

Mikles B, Bhatia M, Oyeku SO, Jin Z, Green NS.

J Pediatr Hematol Oncol. 2014 Oct;36(7):566-71. doi: 10.1097/MPH.0000000000000147.

37.

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.

Green NS, Barral S.

Pediatr Res. 2014 Jan;75(1-2):196-204. doi: 10.1038/pr.2013.227. Epub 2013 Nov 19. Review.

38.

Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children.

Kemper AR, Green NS, Calonge N, Lam WK, Comeau AM, Goldenberg AJ, Ojodu J, Prosser LA, Tanksley S, Bocchini JA Jr.

Genet Med. 2014 Feb;16(2):183-7. doi: 10.1038/gim.2013.98. Epub 2013 Aug 1.

PMID:
23907646
39.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709. Epub 2013 Feb 7.

40.

Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.

Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS.

Pediatr Blood Cancer. 2013 Apr;60(4):653-8. doi: 10.1002/pbc.24381. Epub 2012 Nov 5.

41.

Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity.

Wang Y, Kennedy J, Caggana M, Zimmerman R, Thomas S, Berninger J, Harris K, Green NS, Oyeku S, Hulihan M, Grant AM, Grosse SD.

Genet Med. 2013 Mar;15(3):222-8. doi: 10.1038/gim.2012.128. Epub 2012 Sep 27.

42.

A framework for key considerations regarding point-of-care screening of newborns.

Kemper AR, Kus CA, Ostrander RJ, Comeau AM, Boyle CA, Dougherty D, Mann MY, Botkin JR, Green NS; United States Secretary of Health and Human Services Advisory Committee.

Genet Med. 2012 Dec;14(12):951-4. doi: 10.1038/gim.2012.89. Epub 2012 Aug 16.

43.

Incomplete follow-up of hemoglobinopathy carriers identified by newborn screening despite reporting in electronic medical records.

Burney M, Schunk K, Oundjian NJ, Younge RG, McCord M, Green NS.

J Natl Med Assoc. 2011 Sep-Oct;103(9-10):852-6.

PMID:
22364053
44.

Female factor IX deficiency due to maternally inherited X-inactivation.

Esquilin JM, Takemoto CM, Green NS.

Clin Genet. 2012 Dec;82(6):583-6. doi: 10.1111/j.1399-0004.2012.01842.x. Epub 2012 Jan 30.

PMID:
22233509
45.

Awareness of sickle cell among people of reproductive age: Dominicans and African Americans in northern Manhattan.

Siddiqui S, Schunk K, Batista M, Adames F, Ayala P, Stix B, Rodriguez J, McCord M, Green NS.

J Urban Health. 2012 Feb;89(1):53-8. doi: 10.1007/s11524-011-9618-x.

46.

Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea.

Ender KL, Lee MT, Sheth S, Licursi M, Crotty J, Barral S, Green NS.

J Pediatr Hematol Oncol. 2011 Oct;33(7):496-9. doi: 10.1097/MPH.0b013e31822dcc21.

47.

Neonatal cyanosis from a hemoglobin variant.

Ostrander RJ, Green NS.

N Engl J Med. 2011 Jul 28;365(4):378. doi: 10.1056/NEJMc1106570. No abstract available.

PMID:
21793761
48.

Weighing the evidence for newborn screening for Hemoglobin H disease.

Kemper AR, Knapp AA, Metterville DR, Comeau AM, Green NS, Perrin JM.

J Pediatr. 2011 May;158(5):780-3. doi: 10.1016/j.jpeds.2010.10.042. Epub 2010 Dec 16. Review.

PMID:
21167500
49.

Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.

Green NS, Barral S.

Pediatr Blood Cancer. 2011 Feb;56(2):177-81. doi: 10.1002/pbc.22754. Epub 2010 Sep 9. Review.

50.

Weighing the evidence for newborn screening for early-infantile Krabbe disease.

Kemper AR, Knapp AA, Green NS, Comeau AM, Metterville DR, Perrin JM.

Genet Med. 2010 Sep;12(9):539-43. doi: 10.1097/GIM.0b013e3181e85721. Review.

PMID:
20601893

Supplemental Content

Loading ...
Support Center